Progress of clinical research studies on tuberous sclerosis complex‐related epilepsy in China

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous syndrome, with 75.6%–83.5% and 54.1% patients presenting with epilepsy and drug‐resistant epilepsy (DRE), respectively. Clinical studies on TSC, particularly surgical interventions, have achieved rapid and substantial progress. The TSC‐Task Force Committee of the China Association Against Epilepsy (CAAE‐TFTSC) was founded in 2012, and annual academic conferences on the surgical treatment of TSC‐related epilepsy have been held since 2013. ‘China experts' consensus on surgical treatment of TSC‐related epilepsy’ was published in 2019. This review focuses on surgical treatment, including resective surgery, neuromodulations, corpus callosotomy and mini‐invasive ablations, as well as studies on phenotype, genotype and anti‐seizure therapies of mammalian target of rapamycin inhibitor, vigabatrin and ketogenic diet in patients with TSC‐related DRE in China.

Editorial

“…In addition, other causes such as genetic and autoimmune factors received extensive attention. Liu et al focused on the phenotype, genotype, and management of tuberous sclerosis related epilepsy in their review “Progress of clinical research on tuberous sclerosis complex‐related epilepsy in China.” 6 Li et al summarized the patterns in AE with different antibodies detected and the clinical outlook for the wide application of FDG‐PET in their review “Positron emission tomography in autoimmune encephalitis: clinical implications and future directions.” 7 Tang et al focused on Rasmussen's encephalitis (RE), summarizing the pathogenesis and treatment of RE based on current research in their review “Progress in pathogenesis and therapy of Rasmussen's encephalitis.” 8 …”